Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.

Emulate won a $2 million grant from the National Institutes of Health (NIH)’s National Center for Advancing Translational Sciences, to be used to send one of the Boston-based company’s Organ-Chips to the International Space Station in March 2019.

Boston-based Emulate closed on a Series C round worth $36 million, led by Founders Fund.